Haemophilus influenzae b Antibody, IgG
Also known as: HIBE IGG
Use
This test is used to evaluate the ability of a patient to produce antibody to a protein conjugated bacterial (H. influenza) vaccine, which can help rule out antibody deficiency. Responder status is assessed based on the ratio of post-vaccination concentration to pre-vaccination concentration of Haemophilus influenza b antibody, IgG, determining whether a patient is a good responder, weak responder, or non-responder.
Special Instructions
The 'Pre' and 'Post' Haemophilus influenzae b vaccination specimens should be submitted together for testing. The 'Post' specimen must be drawn 30 days after immunization and must be received within 60 days of the 'Pre' specimen. Specimens should be clearly marked as 'Pre-Vaccine' or 'Post-Vaccine'.
Limitations
This test has not been approved by the US Food and Drug Administration but is performed in a CLIA certified laboratory for clinical purposes. Therefore, its performance characteristics were determined by ARUP Laboratories.
New York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 11256-5
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.15 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection. Transfer to ARUP Standard Transport Tube and mark specimens clearly as 'Pre-Vaccine' or 'Post-Vaccine'.
Storage Instructions
Refrigerated
Causes for Rejection
Plasma or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year (avoid repeated freeze/thaw cycles) |